



1-Ful

PATENT
Attorney Docket No. 8702.0198-00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
)
Jean-Christophe RENAULD et al.) Group Art Unit: 1646
)
Application No.: 09/919,162) Examiner: Dong Jiang
)
Filed: July 31, 2001)
)
For: ISOLATED NUCLEIC ACID) Confirmation No.: 3161
MOLECULES WHICH ENCODE A)
SOLUBLE IL-TIF RECEPTOR OR)
BINDING PROTEIN WHICH)
BINDS TO IL-TIF/IL-22, AND)
USES THEREOF)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

**CERTIFICATE UNDER 37 C.F.R. § 3.73(b), CHANGE OF ADDRESS, REVOCATION
OF POWER OF ATTORNEY AND GRANT OF NEW POWER OF ATTORNEY**

The undersigned, a representative authorized to sign on behalf of the assignee owning all of the interest in this patent application, hereby revokes all previous powers of attorney or authorization of agent granted in this application before the date of execution hereof. The undersigned verifies that Wyeth is the assignee of the entire right, title, and interest in the patent application identified above by virtue of a chain of title from the inventor(s) of the patent application identified above to the current assignee as follows:

1. From: Jean Christophe Renauld and Laure Dumoutier
To: Ludwig Institute for Cancer Research

The document was recorded in the United States Patent and Trademark Office at Reel 012242, Frame 0408.

2. From: Ludwig Institute for Cancer Research
To: Wyeth

The document is being submitted to the Patent and Trademark Office for recordation concurrently with this paper. A copy of the assignment is attached.

As required by 37 C.F.R. 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 C.F.R. § 3.11.

The undersigned hereby grants its power of attorney to the patent practitioners associated with:

Wyeth/Finnegan, Henderson, LLP, Customer Number 60,949.

The undersigned authorizes these practitioners to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith, and to receive the Letters Patent.

Please also send all future correspondence concerning this application to the address associated with the above-identified customer number.

Dated: Feb 5 2007

By: 

Gale F. Matthews
Assistant Secretary
Wyeth



EXHIBIT B

ASSIGNMENT OF PATENTS

This ASSIGNMENT OF PATENTS is made and entered into this 26th day of June, 2006 by and between Ludwig Institute for Cancer Research, a Swiss not for profit corporation with its registered office at Stadelhoferstrasse 22, 8001, Zurich, Switzerland and having an office at 605 Third Avenue, New York, New York 10158 U.S.A. ("Assignor"), and Wyeth, , acting through its Wyeth Pharmaceuticals Division, a corporation organized and existing under the laws of the State of Delaware and having a place of business at 500 Arcola Road, Collegeville, Pennsylvania 19426 U.S.A. ("Assignee").

RECITALS

Assignee and Assignor are parties to a Patent Assignment Agreement dated as of June __, 2006 (the "Agreement"), pursuant to which Assignor has agreed to sell to Assignee and Assignee has agreed to buy from Assignor certain patent rights described herein. In connection therewith, Assignor has agreed to execute a separate Assignment of Patents in order more effectively to assign, transfer, grant, convey, assure and confirm to Assignee and its successors and assigns, or to aid and assist in the collection of or reducing to possession by the Assignee of, all of such patent rights.

In accordance with such Patent Assignment Agreement, Assignor desires to transfer and assign to Assignee, and Assignee desires to accept the transfer and assignment of, all of Assignor's worldwide right, title, and interest in, to and under the patents and patent applications described in Exhibit A attached hereto and incorporated herein by reference and all inventions described therein, together with all divisions, continuations, and continuations-in-part thereof, patents which may be granted thereon, all extensions, renewals, reexaminations and reissues thereof, and all rights, claims, credits, judgments, choses in action, rights of set-off and rights for past, present and future infringement against third parties relating to any of the foregoing, and all rights to claim and contest priority on the basis of any of the foregoing (collectively, the "Patent Rights").

NOW, THEREFORE, Assignor, for good and valuable consideration, the receipt of which is hereby acknowledged, does hereby transfer and assign to Assignee, and Assignee hereby accepts the transfer and assignment of, all of Assignor's worldwide right, title, and interest in, to, and under the Patent Rights, the same to be held and enjoyed by the said Assignee, and its successors and assigns from and after the date hereof as fully and entirely as the same would have been held and enjoyed by the said Assignor had this Assignment of Patents not been made.

Except to the extent that federal law preempts state law with respect to the matters covered hereby, this Assignment of Patents shall be governed by and construed in accordance with the laws of The State of New York without regard to any choice of law principle that would dictate the laws of another jurisdiction.

Capitalized terms used herein without definition shall have the respective meanings ascribed to them in the Agreement.

IN WITNESS WHEREOF, Assignor has caused its duly authorized officer to execute this Assignment of Patents as of the date first above written.

LUDWIG INSTITUTE FOR CANCER RESEARCH

By: Edward A. McDermott, Jr.
Name: Edward A. McDermott, Jr.
Title: President

By: Jonathan C.A. Skipper
Name: Jonathan C.A. Skipper, Ph.D.
Title: Executive Director

THE STATE OF NEW YORK

County of NEW YORK

JONATHAN C.A. SKIPPER
EDWARD A. McDERMOTT, JR. This instrument was executed before me on this 26th day of June, 2006, by Jonathan C.A. Skipper (name), the Executive Director (title) of Ludwig Institute for Cancer Research, a Swiss not for profit corporation, on behalf of said corporation.

WITNESS my hand and official seal.

Kathleen C. Meaghan
Notary Public in and for The State of New York

Printed or Typed Name of Notary

My Commission Expires _____

KATHLEEN C. MEAGHAN
Notary Public, State of New York
No. 01ME4625130
Qualified in Richmond County
Certificate Filed in New York County
Commission Expires Dec 31, 2006

IN WITNESS WHEREOF, Assignee has caused its duly authorized officer to execute this Assignment of Patents as of the date first above written.

WYETH, acting through its Wyeth Pharmaceuticals Division

By: R. J. Smith
Name: Robert J. Smith
Title: Senior Vice President

THE COMMONWEALTH OF PENNSYLVANIA

County of Montgomery

This instrument was executed before me on this 28 day of JUNE, 2006, by ROBERT J. SMITH (name), the SENIOR VICE PRESIDENT (title) of Wyeth, a Delaware corporation acting through its Wyeth Pharmaceuticals Division, on behalf of said corporation.

WITNESS my hand and official seal.

Judith A. Johnston
Notary Public in and for The Commonwealth of Pennsylvania

NOTARIAL SEAL
JUDITH A. JOHNSTON, Notary Public
Upper Providence Twp., Montgomery County
My Commission Expires Sept. 12, 2006

Printed or Typed Name of Notary

My Commission Expires _____

EXHIBIT A TO ASSIGNMENT OF PATENTS

PATENTS AND PATENT APPLICATIONS

I. Patents and Patent Applications Directed to IL-22 and anti IL-22 Antibodies.

Country	Filing Date	Application No	Status	Patent No/ Publication No	LICR ref
Australia	Oct. 18, 1999	6520699	Granted	760224*	5543.2
Australia	Jun. 27, 2001	7303301	Pending	2001273033	5664
Canada	Oct. 18, 1999	2347066	Pending	2347066	5543.2
Canada	Jun. 27, 2001	2416820	Pending	2416820	5664
China	Oct. 18, 1999	99814859.8	Granted	ZL99814859.8 *	5543.2
China	Jun. 27, 2001	01813125 200510116997.8	Pending	1443241	5664
Europe	Oct. 18, 1999	99953231	Pending	1131333	5543.2
Europe	Jun. 27, 2001	01952260	Pending	1305419	5664
Japan	Oct. 18, 1999	2000578328	Granted	3769189*	5543.2
Japan	Jun. 27, 2001	2002516309	Pending	2004/504842	5664
USA	Oct. 26, 1998	09/178,973	Granted	6,274,710*	5543
USA	Jul. 16, 1999	09/354,243	Granted	6,359,117*	5543.2
USA	Oct. 18, 1999	09/419,568	Granted	6,331,613*	5543.1
USA	Dec. 29, 2001	09/751,797	Pending	2001/024652	5543.3
USA	Jul. 26, 2002	10/206,274	Pending	2003/012788	5776
USA	Jul. 25, 2003	10/627,273	Pending	2004/0110189	5543.4
USA	Jul 7, 2005	11/177,987	Pending	2005/0271619	5664.1
PCT	Oct. 18, 1999	PCT/US99/24424		WO 00/24758	5543.2
PCT	Jun. 27, 2001	PCT/US01/20485		WO 02/10393	5664

* Issued Patents

**II. Patents and Applications Directed to IL-22 Soluble Receptors
(IL-22 Receptor and IL-20 Receptor β Complex)**

Country	Filing Date	Application No	Status	Patent No/ Publication No	LICR ref
Australia	Jul 24, 2002	2002322657	Pending	---	5734.1
Europe	Jul 24, 2002	02756665.2	Pending	1527178	5734.1
Japan	Jul 24, 2002	2003515641	Pending	2005508879	5734.1
USA	Jul. 26, 2001	09/915,735	Pending	2003/023033	5734
USA	Jul. 24, 2002	10/483,920	Pending	2004/0236075	5734.1
PCT	Jul. 24, 2002	PCT/US02/23694	Expired	WO 03/010290	5734.1

III. Patents and Applications Directed to IL-22 Soluble Binding Protein

Country	Filing Date	Application No	Status	Patent No/ Publication No	LICR ref
Australia	Sept. 21, 2001	9291801 2001292918	Pending	01/92918	5684.3
Canada	Sept. 21, 2001	2423181	Pending	2423181	5684.3
Europe	Sept. 21, 2001	01973326.0	Pending	1320605	5684.3
Japan	Sept. 21, 2001	2002529505	Pending	2004526413	5684.3
USA	Jul. 31, 2001	09/919,162	Pending	2004/071699	5684.2
USA	March 11, 2003	10/385586	Pending	2004/0180399	5684.3
PCT	Sept. 21, 2001	PCT/US01/29576	Expired	WO 02/24912	5684.3

IV. Abandoned Patents

Country	Filing Date	Application No	Abandon Date	Patent No/ Publication No	LICR ref
Brazil	Oct. 18, 1999	9914777-7	8/10/04	9914777	5543.2
Canada	Jul 24, 2002	2454802	4/21/05	2454802	5734.1
USA	Jul. 27, 2000	09/626,617	10/31/05	-	5664